Read More General business news Lilly to expand into cardiovascular gene editing with Verve Therapeutics acquisition Eli Lilly’s $1.3B acquisition of Verve Therapeutics targets breakthrough one-time gene therapies for high-risk cardiovascular patients. Read more. byPallavi MadhirajuJune 17, 2025